

G. Literaturliste:

1. Herman AR. The history of skin grafts. *J Drugs Dermatol* 2002 Dec; 1(3): 298-301
2. Taniguchi S, Cooper DK. Clinical xenotransplantation: past, present and future. *Ann R Coll Surg Engl.* 1997 Jan; 79(1):13-9
3. Jurkiewicz MJ. Nobel Laureate: Joseph E. Murray, clinical surgeon, scientist, teacher. *Arch Surg.* 1990 Nov; 125(11):1423-3
4. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *S Afr Med J.* 1967 Dec 30;41(48):1271-4
5. Welch CS. A note on transplantation of the whole liver in dogs. *Transplant-Bull* 1955; 54-5
6. Starzl TE, Marchiro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. *Surg-Gyn-Obst* 1963; 117:659-76
7. Wood RP, Ozaki CF, Katz SM, Monsour HP, Dyer CH, Johnston TD. Liver
8. Toledo-Pereyra LH, Simmons RL, Najarian JS. Factors determining successful liver preservation for transplantation. *Ann Surg.* 1975 Mar; 181(3):289-98
9. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. *Wien Klin Wochenschr.* 2002 Jun 28;114(12):433-7
10. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors *Lancet.* 1978 Dec 23-30;2(8104-5):1323-7
11. Neuhaus P, Steffen R, Blumhardt G, Bechstein WO, Lemmens P, Keck H, Rossaint R, Slama R. Verbesserte Überlebenschancen nach Lebertransplantation durch Verminderung perioperativer Komplikationen. *Z Gastroenterol* 1991; 29 (Suppl.2): 169-72
12. Neuhaus P, Blumhardt G, Bechstein WO, Platz KP, Jonas S, Müller AR, Langrehr JM, Lohmann R, Schattenfroh N, Knoop M, Keck H, Lemmens P, Raakow R, Lüsebrink R, Slama KP, Lobeck H, Hopf U. Comparison of FK506 – and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. *Transplantation* 1995; 59 (1): 31-40

13. Gordon RD, Iwatsuki S, Esquivel CO, Makowka L, Tzakis AG, Todo S, Starzl TE. Liver Transplantation. In: Cerilli GJ (Hrg.): Organ Transplantation and Replacement, J.B. Lippincott Company, Philadelphia 1988; 511-34
14. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK506 for Liver, Kidney and Pancreas Transplantation. *Lancet* 1989; 2(8670): 1000-4
15. Busuttil RW, Holt CD. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. *Transplant-Proc.* 1997;29:534-8
16. Platz KP, Müller AR, Zytowski M, Lemmens P, Lobeck H, Neuhaus P. Management of acute steroid-resistant rejection after liver transplantation. *World-J-Surg.* 1996; 20 (8): 1052-8
17. Platz KP, Müller AR, Zytowski M, Bechstein WO, Blumhardt G, Lobeck H, Neuhaus P. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. *Transplant-Proc.* 1995, 27 (1): 1111-3
18. Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R. FK506 treatment of intractable rejection after liver transplantation. *Transplant-Proc.* 1993; 25 (4): 2686-7
19. McMaster P, Buist L. FK 506 in transplantation. *Transplant-Proc.* 1993; 25 (4): 2684-5
20. Deutsche Stiftung für Organtransplantation.
21. Bismuth H, Azoulay D, Demnison A. Recent developments in liver transplantation. *Transplant-Proc.* 1993; 25 (4): 2191-4
22. Johnston TD, Ranjan D. Extending liver transplantation: reduced-size-, split-, and living-donor grafts. *Hepatogastroenterology* 1998 Sep-Oct;45 (23): 1391-4
23. Pirenne J, Koshiba T. Present status and future prospects in liver transplantation. *Int Surg* 1999 Oct-Dec; 84(4): 297-304
24. Dominguez EA. Long-term infectious complications of liver transplantation. *Sem-Liver-Dis* 1995;15 (2): 133-8
25. Kibbler CC. Infections in liver transplantation: risk factors and strategies for prevention. *J-Hosp-Infect* 1995; 30 (Suppl.): 209-17
26. Winston DJ, Emmanouilides C, Bustuttil RW. Infections in liver transplant recipients. *Clin-Infect-Dis.* 1995; 21 (5): 1077-89
27. Markin RS, Stratta RJ, Woods GL. Infection after liver transplantation. *Am-J-Surg-Path* 1990; 14 (Suppl. 1): 74-8
28. Saliba F, Ephraim R, Mathieu D, Samuel D, Richet, H, Castaing D, Bismuth H. Risk Factors For Bacterial Infection After Liver Transplantation. *Transplant-Proc.* 1994; 26 (1): 266

29. Keck H, Langrehr JM, Knoop M, Lohmann R, Bechstein WO, Blumhardt G, Neuhaus P. Reconstruction of bile duct using the side-to-side anastomosis in 389 orthotopic liver transplantations. *Transplant-Proc.* 1995; 27 (1): 1250-1
30. Wiesner, Hermans et al. Selective Bowel Decontamination to decrease gramnegative aerobic bacterial and Candida Colonization and prevent infection after Orthotopic Liver Transplantation. *Transplantation* 45: 570, 1988)
31. Snover DC, Freese DK, Sharp HC, Bloomer JR, Najarian, JA, Asher N (1987). Liver allograft rejection: an analysis of the use of biopsy in determining outcome of rejection. *Am J Surg Path* 11: 1-10
32. Adams DH, Neuberger J (1990). Patterns of liver allograft rejection, *J Hepatol* 10: 113-119
33. Neuhaus P, Bechstein WO, Lefebvre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. *Lancet.* 1989 Oct 14;2(8668):924-5.
34. Miyazono K, Ichijo H, Heldin C.-H. Mini-Review TGF- β : Latent Forms, Binding Proteins and Receptors, *Growth Factors*, 8:11-22; 1993
35. Roberts AB, Sporn MB. Mini Review: Physiological Actions and Clinical Applications of TGF- β , *Growth Factors*, 8:1-9; 1993
36. Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. Modulation of the Immune Response by TGF- β , *Int Arch Allergy Immunol.* 1992; 99:1-7
37. Lahm H, Odartchenko N. Mini Review: Role of TGF- β in Colorectal Cancer, *Growth Factors*, 9:1-9; 1993
38. Meager A. Assays for Transforming Growth Factor, *J. Immunol. Methods*, 141:1-14; 1991
39. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, Monoclonal Antibodies Recognizing TGF- β , *J Immunol.*, 142:1536-1541, No 5; March 1989
40. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. Expression and Secretion of Type Transforming Growth Factor by Activated Human Macrophages. *Proc Natl Acad Sc* 84:6020-6024; September 1987
41. Nath RN, LaRegina M, Markham H, Ksander GA, Weeks PM, The Expression of TGF- β in Fetal and Adult Rabbit Skin Wounds. *J Ped Surg*, Vol 29, No 3 (March); 1994: pp 416-421
42. Coupes BM, Newstead CG, Short CD, Brenchley PEC. TGF- β 1 in Renal Allograft Recipients, *Transplantation*, 57: 1727-1731, No. 12, June 1994

43. Mokhtarian F, Shi Y, Shirazian D, Morgante L, Miller A, David G. Defective Production of Anti-Inflammatory Cytokine, TGF- β by T Cell Lines of Patients with Active Multiple Sclerosis. *J. Immuno*, 1994; 152:6003
44. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, Wahl SM. Immune Dysregulation in TGF- β 1-Deficient Mice, *J. Immuno*, 1994, 153:1936
45. Rove PM. Clinical potential for TGF- β . *Lancet*, 344:72-73, July 9, 1994
46. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF- β receptor. *Nature*, Vol 370, 4 August, 1994
47. Serra R, Carbonetto S, Lord M, Isom HC. TGF- Suppresses Transformation in Hepatocytes by Regulating Integrin Expression. *Cell Growth & Differentiation*, 5:509-517, May1994
48. Gaciong Z, Koziak K, Religa P, Lisiecka A, Morzycka-Michalik M, Rell K, Kozłowska B, Lao M. Increased Expression of Growth Factors During Chronic Rejection in Human Kidney Allograft Transplantation Proceedings. Vol 27, No 1 (February), 1995:928-929
49. Rehmann JA, LeBien TW. TGF- β regulates normal human pre-B cell differentiation, *Int. Immunol.* 6:315-322; 1994
50. Fontana A, Constam DB, Frei K, Malipiero U, Pfister H W. Modulation of the Immune Response by TGF- β , *Int. Arch. Allergy Immunol.* 1992; 99:1-7
51. Ramadori G, Neubauer K, Odenthal M, Nakamura T, Knittel T, Schwögler S, Meyer zum Büschenfelde K-H. The Gene of Hepatocyte Growth Factor is Expressed in Fat-Storing Cells of Rat Liver and is Downregulated During Cell Growth and by TGF- β , *Biochem. Biophys. Res. Comm.*, 183:739-742, No 2, March 16, 1992
52. Annoni G, Weiner FR, Zern MA. Increased TGF- β 1 Gene Expression in Human Liver Disease, *J. Hepatology*, 14:259-264, 1992
53. Francavilla A, Azzarone A, Carrieri G, Scotti-Foglieni C, Zeng Q-H, Cillo U, Porter U, Starzl TE. Effect on the Canine Eck Fistula Liver of Intraportal TGF- β Alone or with Hepatic Growth Factors. *Hepatology*, 16:1267-1270, 1992
54. Gohda E, Matsunaga T, Kataoka H, Yamamoto I. TGF- β is a Potent Inhibitor of Hepocyte Growth Factor Secretion by Human Fibroblasts, *Cell Biol. Int. Reports*, 16:917-926, No 9, 1992
55. Hooper WC, The Role of TGF- β in Hematopoiesis. A Review. *Leukemia Research*, 15:179-184, Vol. 15, 1991

56. Oberhammer F, Bursch W, Parzefall W, Breit P, Erber E, Stadler M, Schulte-Hermann R. Effect of TGF- β on Cell Death of Cultured Rat Hepatocytes *Cancer Res.*, 51:2478-2485, May 1, 1991
57. Adams DH, Hathaway M, Shaw J, Burnett D, Elias E, Strain AJ. TGF- β Induces Human T Lymphocyte Migration in Vitro, *J. Immunology*, 147:609-612, No 2, July 15, 1991
58. Castilla A, Prieto J, Fausto N. TGF- β 1 and β 2 in Chronic Liver Disease Effects of Interferon Alpha Therapy. *New Eng. J. Med.*, 324:933-40, 1991
59. Milani S, Herbst H, Schuppan D, Stein H, Surrenti C. Rapid Communication TGF- β 1 and β 2 are Differentially Expressed in Fibrotic Liver Disease. *Am. J. Path.*, 139:1221-1229, No 6, December 1991
60. Jakowlew SB, Mead JE, Danielpour D, Wu J, Roberts AB, Fausto N. TGF- β Isoforms in Rat Liver Regeneration: Messenger RNA Expression and Activation of Latent TGF- β . *Cell Regulation*, 2:535-548, July 1991
61. Lee G, Ellingsworth LR, Gillis S, Wall R, Kincade PW. Transforming Growth Factors are Potential Regulators of B Lymphopoiesis, *J. Exp. Med.*, 166:1290-1299, November 1987
62. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the Chemotactic Migration of Human Fibroblasts by TGF- β , *J. Exp. Med.*, 165:251-256, January 1987
63. Bachem MG, Schüftan G, Schirmmacher P, Gressner AM. Feedback Mechanisms between M and TGF-1 Reduce Extracellular Matrix Synthesis of Liver Fat-Storing Cells, *Ann. N. Y. Acad. Sci.* 1994, Sep 10; 737:421-4
64. Qin L, Chavin KD, Ding Y, Woodward JE, Favaro JP, Lin J, Bromberg JS. Gene Transfer for Transplantation, Prolongation of Allograft Survival with TGF-1, *Ann. of Surgery*, 220:508-519, No 4, 1994
65. Baldwin RL, Korc M. Growth Inhibition of Human Pancreatic Carcinoma Cells by TGF- β 1, *Growth Factors*, 8:23-34, 1993
66. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino Jr. MA. Inhibition of Cytokine Production by Cyclosporine A and TGF- β , *J. Exp. Med.*, 166:571-576, 1987
67. Wahl S M, Hunt DA, Bansal G, McCartney-Francis N, Ellingsworth L, Allen JB. Bacterial Cell Wall-Induced Immunosuppression: Role of TGF- β . *J. Exp. Med.*, 168:1403-1417, October, 1988
68. McCartney-Francis NL, Wahl SM. TGF- β : A Matter of Life and Death, *J. Leukocyte Biololy*, 55:401-409, March, 1994

69. Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI. Neutrophil Chemotaxis in Response to TGF- β Isoforms (TGF- β 1, TGF- β 2, TGF- β 3) is Mediated by Fibronectin, *J. Immunology*, 152:2456-2466, 1994
70. Verbanac KM, Carver FM, Haisch CE, Thomas JM. A Role for TGF- β in the Veto Mechanism in Transplant Tolerance, *Transplantation*, 57:893-900, No 6, March, 1994
71. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained Expression of TGF- β 1 underlies development of Progressive Kidney Fibrosis, *Kidney Int.*, 45:916-927, 1994
72. Holter W, Kalthoff FS, Pickl WF, Ebner C, Majdic O, Kraft D, Knapp W. TGF- β Inhibits IL-4 and IFN- Production by Stimulated Human T Cells, *Int. Immunol.*, 6:469-475, No 3, 1994
73. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matzuzawa Y. Plasma TGF- β 1 in Patients with Hepatocellular Carcinoma, *Cancer*, 73:2275-2279, 1994
74. Häyry P, Alatolo S, Myllärniemi M, Räisänen-Sokolowski A, Lemström K. Cellular and Molecular Biology of Chronic Rejection, *Transplantation Proceedings*, 27:71-74, No 1, 1995
75. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated Plasma Levels of TGF- β 1 in Patients with Invasive Prostate Cancer. *Nature Medicine*, 1: 282-284, No 4, April 1995
76. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC. Evidence That TGF- β Can Inhibit Human T-Lymphocyte Proliferation through Paracrine and Autocrine Mechanisms. *Cell. Immunol.*, 150:45-58, 1993
77. Chen R-H, Ebner R, Derynck R. Inactivation of the Type II Receptor Reveals Two Receptor Pathways for the Diverse TGF- β Activities. *Science*, 260:1335-1338, May 1993
78. Ayala A, Meldrum DR, Perrin MM, Chaudry IH. The Release of TGF- β following Haemorrhage: Its Role as a Mediator of Host Immunosuppression. *Immunology*, 79:479-484, 1993
79. Kondo S, Isobe K, Ishiguro N, Nakashima I, Miura T. TGF- β 1 Enhances the Generation of Allospecific Cytotoxic T Lymphocytes. *Immunology*, 79:459-464, 1993
80. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powles T, Coombes RC. The Prognostic Significance of Transforming Growth Factors in Human Breast Cancer. *Br. J. Cancer*, 67:1408-1412, 1993
81. Meager A. Assays for Transforming Growth Factor. *J. Immunol. Methods*, 141:1-14, 1991

82. Hayashi M, Martinez OM, Garcia-Kennedy R, So S, Esquivel CO, Krams SM. Expression of cytokines and immune mediators during chronic liver allograft rejection. *Transplantation*. 1995 Dec 27;60(12):1533-8.
83. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory roles of TGF-beta. *Immunol Today*. 1989 Aug;10(8):258-61
84. Qin L, Chavin KD, Ding Y, Favaro JP, Woodward JE, Lin J, Tahara H, Robbins P, Shaked A, Ho DY, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. *Transplantation*. 1995 Mar 27;59(6):809-16.
85. Waltenberger J, Wanders A, Fellstrom B, Miyazono K, Heldin CH, Funai K. Induction of transforming growth factor-beta during cardiac allograft rejection. *J Immunol*. 1993 Jul 15;151(2):1147-57.
86. Zhao XM, Frist WH, Yeoh TK, Miller GG. Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-beta (TGF-beta) with histological rejection. *Clin Exp Immunol*. 1993 Sep;93(3):448-51.
87. Charpin JM, Valcke J, Kettaneh L, Epardeau B, Stern M, Israel-Biet D. Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection. *Transplantation*. 1998 Mar 15;65(5):752-5.
88. Krams SM, Egawa H, Quinn MB, Villanueva JC, Garcia-Kennedy R, Martinez OM. Apoptosis as a mechanism of cell death in liver allograft rejection. *Transplantation*. 1995 Feb 27;59(4):621-5.
89. Loong CC, Chen A, Lui WY, King KL, Lin CY. Expression of cytokines, growth factors, and adhesion molecules in rejecting human renal allograft. *Transplant Proc*. 1996 Jun;28(3):1445-6.
90. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. *J Am Soc Nephrol*. 1995 Aug;6(2):286-94.
91. McCartney-Francis NL, Wahl SM. Transforming growth factor beta: a matter of life and death. *J Leukoc Biol*. 1994 Mar;55(3):401-9.
92. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). *Growth Factors*. 1993;8(1):1-9.
93. Shin GT, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Suthanthiran M. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. *Transplantation*. 1998 Feb 15;65(3):313-8.

94. Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of a transforming growth factor beta-dependent mechanism of inhibition of cell growth. *Transplantation*. 1994 Feb 27;57(4):577-82.
95. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M. Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. *FEBS Lett*. 1995 Jan 23;358(2):109-12.
96. Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmuller T, Christe W, Hopf U, Lobeck H, Neuhaus P. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. *Transplant Proc*. 1995 Feb;27(1):1117-20.